Following a full submission
fesoterodine fumarate prolonged release tablets (Toviaz®) are accepted for restricted use within NHS Scotland for treatment of the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may occur in patients with overactive bladder syndrome.
Fesoterodine is effective in reducing symptoms associated with overactive bladder syndrome without a neurological cause and was of equivalent efficacy to a comparator antimuscarinic agent in one study.
Fesoterodine is associated with adverse effects typical of antimuscarinic agents used in this condition. It is restricted to second-line use as there are cheaper antimuscarinics available that would normally be used as first-line agents.
Download detailed advice96KB (PDF)
- Medicine name:
- fesoterodine fumarate (Toviaz)
- SMC ID:
- Treatment of the symptoms of increased urinary frequency and/or urgency incontinence) that may occur in patients with overactive bladder (OAB) syndrome
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Date advice published
- 07 July 2008